Atrial fibrillation
Not yet recruitingStroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)
Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)
- Disease:Atrial fibrillation
- Substances:REGN9933Human Igg4 S228P Monoclonal Antibody Against Factor Xi And Activated Factor Xi
Bulgaria- Participants:18–64 years · 65+ years
- Substances:REGN9933
- Sponsor:Regeneron Pharmaceuticals Inc.












